Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISA101 + ISA101b + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- ISA Pharmaceuticals
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
This is a **combination regimen** consisting of two synthetic long peptide vaccines (ISA101 and ISA101b), carboplatin (a platinum-based chemotherapy agent), and paclitaxel (a microtubule inhibitor chemotherapeutic), under clinical investigation primarily for **HPV16-positive advanced or recurrent cervical cancer**. ISA101 and ISA101b are therapeutic vaccines composed of synthetic peptides from HPV16 E6 and E7 oncoproteins, designed to elicit a T-cell–mediated immune response against HPV-induced lesions. Carboplatin induces DNA crosslinking to inhibit tumor cell replication, while paclitaxel stabilizes microtubules, inhibiting cell division. The combination aims to leverage vaccine-driven HPV-specific immune activity synergistically with chemotherapy-induced tumor cell killing. Primary developer is ISA Pharmaceuticals, with ISA101 trials in combination with carboplatin and paclitaxel in cervical cancer.
- Other names
- ISA101 + ISA101b + carboplatin + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))HPV16 E6 oncoproteinDNAHPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on ISA101 + ISA101b + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISA101 + ISA101b + carboplatin + paclitaxel.